Age Related Macular Degeneration – Pipeline Review, H2 2016
- Pages: 563
- Published: December 2016
- Report Code: GMDHC8804IDB
Global Markets Direct’s, ‘Age Related Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Age Related Macular Degeneration pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects
The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
3SBio Inc
AC Immune SA
Achillion Pharmaceuticals Inc
Aciont Inc
Acucela Inc
AdAlta Ltd
Adverum Biotechnologies Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Alimera Sciences Inc
Alkeus Pharmaceuticals Inc
Allergan Plc
Allinky Biopharma
Alteogen Inc
Amakem NV
Amarna Therapeutics BV
Ampio Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
ANP Technologies Inc
Apellis Pharmaceuticals Inc
Apexigen Inc
Applied Genetic Technologies Corp
Astellas Pharma Inc
Benitec Biopharma Ltd
Biokine Therapeutics Ltd
BioMAS Ltd
Biomics Biotechnologies Co Ltd
Biophytis SAS
BLR Bio LLC
Boehringer Ingelheim GmbH
Caladrius Biosciences Inc
Catalyst Biosciences Inc
Cell Cure Neurosciences Ltd
Cell Medica Ltd
Charlesson LLC
Chong Kun Dang Pharmaceutical Corp
Cipla Ltd
Clanotech AB
Clearside BioMedical Inc
Coherus BioSciences Inc
Colby Pharmaceutical Company
Crinetics Pharmaceuticals Inc
Critical Pharmaceuticals Ltd
Daiichi Sankyo Company Ltd
Diffusion Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Eleven Biotherapeutics Inc.
Elsalys Biotech SAS
Exonate Ltd
F. Hoffmann-La Roche Ltd
FirstString Research Inc
Foamix Pharmaceuticals Ltd
Formycon AG
Gene Techno Science Co Ltd
Genentech Inc
GenSight Biologics SA
GlaxoSmithKline Plc
Graybug Vision Inc
Grupo Ferrer Internacional SA
HanAll Biopharma Co Ltd
Huabo Biopharm Co Ltd
iCo Therapeutics Inc.
Icon Bioscience Inc
Iconic Therapeutics Inc
Inception Sciences Inc
Innovent Biologics Inc
Intellect Neurosciences Inc
International Stem Cell Corp
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Kala Pharmaceuticals Inc
Kodiak Sciences Inc
Lead Discovery Center GmbH
LeadArtis SL
M's Science Corp
Mabion SA
MacuCLEAR Inc
MeiraGTx Ltd
Mitotech SA
Mitsubishi Tanabe Pharma Corp
Mor Research Application Ltd
Navigen Pharmaceuticals Inc
Navya Biologicals Pvt Ltd
Neovacs SA
Neumedicines Inc
Neuroptis Biotech
Novartis AG
NovelMed Therapeutics Inc
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Omeros Corp
Ophthotech Corp
Oxford BioMedica Plc
PanOptica Inc
Pfenex Inc
Pfizer Inc
Precision Ocular Ltd
Promedior Inc
pSivida Corp
QLT Inc
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Retrotope Inc
Ribomic Inc
RXi Pharmaceuticals Corp
Samumed LLC
SanBio Inc
Santen Pharmaceutical Co Ltd
SciFluor Life Sciences LLC
Stealth BioTherapeutics Inc
Sucampo Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
TRACON Pharmaceuticals Inc
TWi Pharmaceuticals Inc
Tyrogenex Inc
Wellstat Ophthalmics Corp
Xbrane Biopharma AB
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.